


## Bopindolol

<b>Cat. No.:</b>	HY-B1562
<b>CAS No.:</b>	62658-63-3
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>28</sub> N <sub>2</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	380.48
<b>Target:</b>	Adrenergic Receptor; Renin; 5-HT Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Bopindolol ((±)-Bopindolol) is an orally active antagonist of β-adrenoceptors (ARs) with partial agonist activity. Bopindolol is non-selective for β1- and β2-ARs and has low affinity for β3-AR subtype. Bopindolol has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Bopindolol is a prodrug of <a href="#">Pindolol</a> (HY-B0982). Bopindolol can be used for essential and renovascular hypertension research <sup>[1][2][3][4]</sup> .										
<b>IC<sub>50</sub> &amp; Target</b>	β2 adrenoceptor	Beta-1 adrenergic receptor	Beta-3 adrenergic receptor								
<b>In Vivo</b>	<p>Bopindolol (intravenous injection; 8, 16 and 32 μg/kg) causes a dose-dependent inhibition of isoprenaline-induced tachycardia, and this agent is 4 times more potent than propranolol in anaesthetised dogs<sup>[1]</sup>.</p> <p>Bopindolol (0.3, 1 and 3 mg/kg; IP; single dosage) produces dose dependent decreases in diastolic blood pressure and in heart rate<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Wistar rats (260-300 g)<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.3, 1 and 3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>IP; single dosage</td> </tr> <tr> <td>Result:</td> <td>Produced dose dependent decreases in diastolic blood pressure, and the decrease of about 8 mmHg at 3 mg/kg. Decreased the heart rate in a dose-dependent manner.</td> </tr> </table>			Animal Model:	Male Wistar rats (260-300 g) <sup>[2]</sup>	Dosage:	0.3, 1 and 3 mg/kg	Administration:	IP; single dosage	Result:	Produced dose dependent decreases in diastolic blood pressure, and the decrease of about 8 mmHg at 3 mg/kg. Decreased the heart rate in a dose-dependent manner.
Animal Model:	Male Wistar rats (260-300 g) <sup>[2]</sup>										
Dosage:	0.3, 1 and 3 mg/kg										
Administration:	IP; single dosage										
Result:	Produced dose dependent decreases in diastolic blood pressure, and the decrease of about 8 mmHg at 3 mg/kg. Decreased the heart rate in a dose-dependent manner.										

### REFERENCES

- [1]. Nagatomo T, et al. Bopindolol: pharmacological basis and clinical implications. *Cardiovasc Drug Rev.* 2001 Spring;19(1):9-24.
- [2]. Harron DW, et al. Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. *Drugs.* 1991 Jan;41(1):130-49.
- [3]. H Tanaka, et al. Hypotensive effect of bopindolol in pithed rats. *Gen Pharmacol.* 1993 Mar;24(2):373-5.
- [4]. Y Hosohata, et al. Bopindolol is a slowly dissociating beta 1-adrenoceptor antagonist when compared to other beta-blockers. *Biol Pharm Bull.* 1995 Aug;18(8):1066-71.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA